Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28283221 | 0.88 | HIF1A (0.46) | TSHRATMATRHIF1AMAPT | |
| Piperazine SCHEMBL27676610 | 0.88 | HIF1A (0.46) | TSHRATMATRHIF1AMAPT | |
| Piperazine SCHEMBL3767537 | 0.85 | HIF1A (0.43) | TSHRATMATRHIF1AMAPT | |
| Piperazine SCHEMBL18091103 | 0.85 | HIF1A (0.43) | TSHRATMATRHIF1AMAPT | |
| Piperazine SCHEMBL989787 | 0.85 | HIF1A (0.43) | TSHRATMATRHIF1AMAPT | |
| Aziridine SCHEMBL29603143 | 0.83 | — | — | |
| Piperazine SCHEMBL28520413 | 0.82 | HIF1A (0.40) | TSHRATMATRHIF1AMAPT | |
| Piperazine SCHEMBL28068962 | 0.82 | HIF1A (0.40) | TSHRATMATRHIF1AMAPT | |
| Piperidine SCHEMBL9644995 | 0.82 | ALDH1A1 (0.60) | TSHRATMATRHIF1AMAPT | |
| Aziridine SCHEMBL476461 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188079-A | 7 piperazine thioureas of camptothecine, preparation method and purposes | 兰州大学 | 2016-12-07 | — | — | CN | claimed |
| CN-111138358-B | USP8 inhibitor and preparation method and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-111138358-A | USP8 inhibitor and preparation method and application thereof | 中国药科大学 | 2020-05-12 | — | — | CN | disclosed |
| CN-106188079-A | 7 piperazine thioureas of camptothecine, preparation method and purposes | 兰州大学 | 2016-12-07 | — | — | CN | disclosed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
| EP-1309568-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | TSHR 1831/4885ATM 1213/4885ATR 1261/4885 |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | WNK2, CDK5, WNK1 | TSHR 2507/4885ATM 1173/4885ATR 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.